Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil in Type II Diabetic Patients With Hypertension
NCT00403481Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olmesartan in hypertension (HTN), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM. Started Nov 2006; status: completed.
02
Drugs
olmesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00403481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00403481.